NEW YORK (GenomeWeb News) – Pacific Biosciences has filed a prospectus for the resale of up to 5.5 million shares of its stock, issuable upon the exercise of warrants.

The Palo Alto, Calif.-based company is not selling any securities under the prospectus, and while it will receive no proceeds from the sale of shares issuable upon exercise of the warrants, it could receive gross proceeds of about $14.5 million if all of the warrants are exercised for cash, PacBio said in its document filed with the US Securities and Exchange Commission on Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.